Dataset Information

HPLC-MS/MS analysis of plasma samples from patients with colorectal cancer

ABSTRACT: We sought to identify a characteristic profile of proteins in blood plasma samples taken from patients with colorectal cancer using mass spectrometry. We obtained mass spectrometry data of 38 samples from patients with colorectal cancer and 41 samples from healthy volunteers and the data analysis were carried out using panoramic ultra-high resolution mass spectrometry. We carried out a comparative analysis for two series "case" and "control" of protein profiles, differently expressed proteins and proteins with posttranslational modifications.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

DISEASE(S): Colon Cancer

SUBMITTER: Anna Kaysheva

LAB HEAD: Anna Kaysheva

PROVIDER: PXD015163 | Pride | 2020-04-02

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 107

Publications

Revelation of Proteomic Indicators for Colorectal Cancer in Initial Stages of Development.

Kopylov Arthur T AT Stepanov Alexander A AA Malsagova Kristina A KA Soni Deepesh D Kushlinsky Nikolay E NE Enikeev Dmitry V DV Potoldykova Natalia V NV Lisitsa Andrey V AV Kaysheva Anna L AL

Molecules (Basel, Switzerland) 20200131 3

<b>Background:</b> Colorectal cancer (CRC) at a current clinical level is still hardly diagnosed, especially with regard to nascent tumors, which are typically asymptotic. Searching for reliable biomarkers of early diagnosis is an extremely essential task. Identification of specific post-translational modifications (PTM) may also significantly improve net benefits and tailor the process of CRC recognition. We examined depleted plasma samples obtained from 41 healthy volunteers and 28 patients wi ...[more]

PMID: 32023884

Similar Datasets

Project description:Aminoglycoside antibiotics display broad-spectrum activity against Gram-negative and Gram-positive bacteria by targeting their ribosomes. Herein, we have demonstrated that energy metabolism plays a crucial role in aminoglycoside tolerance, as knockout strains associated with the tricarboxylic acid cycle (TCA) and the electron transport chain (ETC) exhibited increased tolerance to aminoglycosides in the mid-exponential growth phase of Escherichia coli cells. Given that aminoglycoside uptake relies on the energy-driven electrochemical potential across the cytoplasmic membrane, our initial expectation was that these genetic perturbations would decrease the proton motive force (PMF), subsequently affecting the uptake of aminoglycosides. However, our results did not corroborate this assumption. We found no consistent metabolic changes, ATP levels, cytoplasmic pH variations, or membrane potential differences in the mutant strains compared to the wild type. Additionally, intracellular concentrations of fluorophore-labeled gentamicin remained similar across all strains. To uncover the mechanism responsible for the observed tolerance in mutant strains, we employed untargeted mass spectrometry to quantify the proteins within these mutants and subsequently compared them to their wild-type counterparts. Our comprehensive analysis, which encompassed protein-protein association networks and functional enrichment, unveiled a noteworthy upregulation of proteins linked to the TCA cycle in the mutant strains during the mid-exponential growth phase, suggesting that these strains compensate for the perturbation in their energy metabolism by increasing TCA cycle activity to maintain their membrane potential and ATP levels. Furthermore, our pathway enrichment analysis shed light on local network clusters displaying downregulation across all mutant strains, which were associated with both large and small ribosomal binding proteins, ribosome biogenesis, translation factor activity, and the biosynthesis of ribonucleoside monophosphates. These findings offer a plausible explanation for the observed tolerance of aminoglycosides in the mutant strains. Altogether, this research has the potential to uncover mechanisms behind aminoglycoside tolerance, paving the way for novel strategies to combat such cells.

			Action	DRS
	Cancer_Colorectal_01.mgf	Mgf
	Cancer_Colorectal_01.raw	Raw
	Cancer_Colorectal_01.xls	Xls
	Cancer_Colorectal_02.mgf	Mgf
	Cancer_Colorectal_02.raw	Raw